610 related articles for article (PubMed ID: 32322066)
1. Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M; Li YY; Boynton AN; Spurr LF; Iorgulescu JB; Bohrson CL; Cortes-Ciriano I; Birzu C; Geduldig JE; Pelton K; Lim-Fat MJ; Pal S; Ferrer-Luna R; Ramkissoon SH; Dubois F; Bellamy C; Currimjee N; Bonardi J; Qian K; Ho P; Malinowski S; Taquet L; Jones RE; Shetty A; Chow KH; Sharaf R; Pavlick D; Albacker LA; Younan N; Baldini C; Verreault M; Giry M; Guillerm E; Ammari S; Beuvon F; Mokhtari K; Alentorn A; Dehais C; Houillier C; Laigle-Donadey F; Psimaras D; Lee EQ; Nayak L; McFaline-Figueroa JR; Carpentier A; Cornu P; Capelle L; Mathon B; Barnholtz-Sloan JS; Chakravarti A; Bi WL; Chiocca EA; Fehnel KP; Alexandrescu S; Chi SN; Haas-Kogan D; Batchelor TT; Frampton GM; Alexander BM; Huang RY; Ligon AH; Coulet F; Delattre JY; Hoang-Xuan K; Meredith DM; Santagata S; Duval A; Sanson M; Cherniack AD; Wen PY; Reardon DA; Marabelle A; Park PJ; Idbaih A; Beroukhim R; Bandopadhayay P; Bielle F; Ligon KL
Nature; 2020 Apr; 580(7804):517-523. PubMed ID: 32322066
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract][Full Text] [Related]
3. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
Sa JK; Choi SW; Zhao J; Lee Y; Zhang J; Kong DS; Choi JW; Seol HJ; Lee JI; Iavarone A; Rabadan R; Nam DH
Int J Cancer; 2019 Jun; 144(12):3023-3030. PubMed ID: 30536544
[TBL] [Abstract][Full Text] [Related]
4. Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.
Liu J; Hu S; Jiang H; Cui Y
Front Immunol; 2024; 15():1369972. PubMed ID: 38690285
[TBL] [Abstract][Full Text] [Related]
5. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Gatto L; Franceschi E; Tosoni A; Nunno VD; Bartolini S; Brandes AA
Immunotherapy; 2022 Jul; 14(10):799-813. PubMed ID: 35670093
[TBL] [Abstract][Full Text] [Related]
6. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
van Thuijl HF; Mazor T; Johnson BE; Fouse SD; Aihara K; Hong C; Malmström A; Hallbeck M; Heimans JJ; Kloezeman JJ; Stenmark-Askmalm M; Lamfers ML; Saito N; Aburatani H; Mukasa A; Berger MS; Söderkvist P; Taylor BS; Molinaro AM; Wesseling P; Reijneveld JC; Chang SM; Ylstra B; Costello JF
Acta Neuropathol; 2015 Apr; 129(4):597-607. PubMed ID: 25724300
[TBL] [Abstract][Full Text] [Related]
7. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Hunter C; Smith R; Cahill DP; Stephens P; Stevens C; Teague J; Greenman C; Edkins S; Bignell G; Davies H; O'Meara S; Parker A; Avis T; Barthorpe S; Brackenbury L; Buck G; Butler A; Clements J; Cole J; Dicks E; Forbes S; Gorton M; Gray K; Halliday K; Harrison R; Hills K; Hinton J; Jenkinson A; Jones D; Kosmidou V; Laman R; Lugg R; Menzies A; Perry J; Petty R; Raine K; Richardson D; Shepherd R; Small A; Solomon H; Tofts C; Varian J; West S; Widaa S; Yates A; Easton DF; Riggins G; Roy JE; Levine KK; Mueller W; Batchelor TT; Louis DN; Stratton MR; Futreal PA; Wooster R
Cancer Res; 2006 Apr; 66(8):3987-91. PubMed ID: 16618716
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Maxwell JA; Johnson SP; McLendon RE; Lister DW; Horne KS; Rasheed A; Quinn JA; Ali-Osman F; Friedman AH; Modrich PL; Bigner DD; Friedman HS
Clin Cancer Res; 2008 Aug; 14(15):4859-68. PubMed ID: 18676759
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide-associated hypermutation in gliomas.
Choi S; Yu Y; Grimmer MR; Wahl M; Chang SM; Costello JF
Neuro Oncol; 2018 Sep; 20(10):1300-1309. PubMed ID: 29452419
[TBL] [Abstract][Full Text] [Related]
10. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
11. Mutational burden and immune recognition of gliomas.
Prost D; Bielle F; Ligon KL; Touat M
Curr Opin Oncol; 2021 Nov; 33(6):626-634. PubMed ID: 34651608
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
[TBL] [Abstract][Full Text] [Related]
13. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas.
Leung SY; Chan TL; Chung LP; Chan AS; Fan YW; Hung KN; Kwong WK; Ho JW; Yuen ST
Am J Pathol; 1998 Oct; 153(4):1181-8. PubMed ID: 9777949
[TBL] [Abstract][Full Text] [Related]
16.
Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Pollack IF; Hamilton RL; Sobol RW; Nikiforova MN; Nikiforov YE; Lyons-Weiler MA; LaFramboise WA; Burger PC; Brat DJ; Rosenblum MK; Gilles FH; Yates AJ; Zhou T; Cohen KJ; Finlay JL; Jakacki RI;
Pediatr Blood Cancer; 2010 Dec; 55(6):1066-71. PubMed ID: 20589656
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Crisafulli G; Sartore-Bianchi A; Lazzari L; Pietrantonio F; Amatu A; Macagno M; Barault L; Cassingena A; Bartolini A; Luraghi P; Mauri G; Battuello P; Personeni N; Zampino MG; Pessei V; Vitiello PP; Tosi F; Idotta L; Morano F; Valtorta E; Bonoldi E; Germano G; Di Nicolantonio F; Marsoni S; Siena S; Bardelli A
Cancer Discov; 2022 Jul; 12(7):1656-1675. PubMed ID: 35522273
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Wood MD; Neff T; Nickerson JP; Sayama C; Raslan AM; Ambady P; Corless CL; Nazemi KJ
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):460-463. PubMed ID: 33296093
[No Abstract] [Full Text] [Related]
20. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
